Ligand Pharmaceuticals (LGND) Operating Leases (2019 - 2026)

Ligand Pharmaceuticals (LGND) has 8 years of Operating Leases data on file, last reported at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 399.12% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 399.12% YoY), and the FY2025 full-year result was $4.2 million, down 41.24% from the prior year.
• Operating Leases eased to $4.0 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $37.3 million in Q3 2022 to a low of $800000.0 in Q1 2025.
• A 5-year average of $10.2 million and a median of $6.3 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 520.18% in 2022 and slumped 84.59% in 2025, its largest moves.
• Tracing LGND's Operating Leases over 5 years: stood at $11.1 million in 2022, then slumped by 47.95% to $5.8 million in 2023, then rose by 24.31% to $7.2 million in 2024, then slumped by 41.24% to $4.2 million in 2025, then slipped by 5.02% to $4.0 million in 2026.
• Business Quant data shows LGND's Operating Leases at $4.0 million in Q1 2026, $4.2 million in Q4 2025, and $4.4 million in Q3 2025.